Peptide research profile

Retatrutide

Also known as LY3437943 · GIP/GLP-1/glucagon triple agonist

An investigational once-weekly agonist of GIP, GLP-1, and glucagon receptors. Human phase 2 data exist, but it is not an approved medicine.

  • Metabolic research
Human trials1 referencesEducational use

Dosing literacy

Dosing & scaling, explained

Retatrutide remains investigational. These are trial arms—not prescribing instructions—and the starting dose materially affected tolerability. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Lower trial arm1 mg / week
    48 weeks

    A fixed lower-dose arm in the phase 2 obesity trial.

  2. Mid trial arms4–8 mg / week
    After 2 or 4 mg starts

    Maintenance exposures tested after different starting strategies.

  3. Highest phase 2 arm12 mg / week
    After a 2 mg start

    The highest maintenance arm; it is not an approved dose.

The in-app 2.5 mg preset is a recorded library row; it was not a maintenance arm in the cited phase 2 trial.

Schedule literacy

Patterns described in source material

  • Once weekly

    All phase 2 obesity arms used weekly subcutaneous administration.

  • Escalated arms

    The 4, 8, and 12 mg groups used defined starting-dose and escalation strategies.

  • Trial protocol only

    Outside a trial there is no regulator-approved schedule.

Clinical context
  • 1, 4, 8, or 12 mg · Once weeklyPhase 2 obesity trialNCT04881760

“Established” here means directly tested in humans, not approved.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Obesity trials

    Phase 2 research tested 1, 4, 8, and 12 mg weekly maintenance groups.

  • 02

    Dose response

    Weight and adverse-event outcomes varied by maintenance and starting dose.

  • 03

    Metabolic endpoints

    Programs examine glycaemia, lipids, liver fat, and cardiometabolic markers.

  • 04

    Heart-rate signal

    Dose-dependent heart-rate increases were reported and monitored in trials.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Randomized phase 2 obesity trial

    The 48-week trial enrolled 338 adults and compared multiple weekly doses with placebo.

  • Human

    Lower starting doses improved tolerability

    Gastrointestinal events were common and were partially mitigated by starting at 2 mg rather than 4 mg.

  • Review

    Still investigational

    No approved retatrutide product or public prescribing schedule exists.

Recorded protocol library

Amounts recorded for Retatrutide

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Lowest phase 2 arm

    1 mg

    Sign in for schedule, duration and source context.

  • 02

    Phase 2 starting amount

    2 mg

    Sign in for schedule, duration and source context.

  • 03

    Conservative phase 2 target cap

    4 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Triple incretin/glucagon receptor agonist
Amino acids
39
Approx. MW
4731.3 Da
Origin / design
Engineered long-acting peptide in clinical development

Important limitations

  • Phase 2 results do not establish an approved regimen or long-term benefit-risk profile.
  • Unregulated products labeled retatrutide cannot be assumed equivalent to trial material.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

1 curated references

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialNew England Journal of Medicine · 2023 · Human

Related profiles